Statins Increase p 21 through Inhibition of Histone Deacetylase Activity and Release of Promoter-Associated HDAC 1 / 2

Statins are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia. Recently, they are reported to have beneficial effects on certain cancers. In this study, we show that statins inhibited the histone deacetylase (HDAC) activity and increased the accumulation of acetylated histone-H3 and the expression of p21 in human cancer cells. Computational modeling showed the direct interaction of the carboxylic acid moiety of statins with the catalytic site of HDAC2. In the subsequent enzymatic assay, it was shown that lovastatin inhibited HDAC2 activity competitively with a Ki value of 31.6 Mmol/L. Sp1 but not p53 sites were found to be the statins-responsive element shown by p21 luciferase-promoter assays. DNA affinity protein binding assay and chromatin immunoprecipitation assay showed the dissociation of HDAC1/2 and association of CBP, leading to the histone-H3 acetylation on the Sp1 sites of p21 promoter. In vitro cell proliferation and in vivo tumor growth were both inhibited by statins. These results suggest a novel mechanism for statins through abrogation of the HDAC activity and promoter histone-H3 acetylation to regulate p21 expression. Therefore, statins might serve as novel HDAC inhibitors for cancer therapy and chemoprevention. [Cancer Res 2008;68(7):2375–83]

[1]  S. Sebti,et al.  Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter , 2007, Oncogene.

[2]  M. Sadeghi,et al.  3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Gartel,et al.  Transcriptional regulation of the p21((WAF1/CIP1)) gene. , 1999, Experimental cell research.

[4]  R. Evans,et al.  Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. , 2000, Molecular cell.

[5]  Nathan A. Baker,et al.  PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations , 2004, Nucleic Acids Res..

[6]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[7]  M. Bialer,et al.  The Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors , 2004, Epilepsia.

[8]  S. Purgato,et al.  p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. , 2005, Oncology reports.

[9]  G. Firestone,et al.  Role of the CCAAT/Enhancer Binding Protein-α Transcription Factor in the Glucocorticoid Stimulation of p21 waf1/cip1 Gene Promoter Activity in Growth-arrested Rat Hepatoma Cells* , 1998, The Journal of Biological Chemistry.

[10]  T. Sakai,et al.  Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. , 1999, Cancer research.

[11]  T. Sakai,et al.  Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. , 1997, Biochemical and biophysical research communications.

[12]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[13]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[14]  M. Hung,et al.  Phosphorylation of CBP by IKKα Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-κB , 2007 .

[15]  Xiao-Fan Wang,et al.  Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21 WAF1/CIP1 in Human Prostate Carcinoma Cells* , 1998, The Journal of Biological Chemistry.

[16]  B. Kaina,et al.  Lovastatin inhibits Rho‐regulated expression of E‐selectin by TNF‐α and attenuates tumor cell adhesion , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  H. Mo,et al.  Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention , 2004, Experimental biology and medicine.

[18]  P. Geerlings,et al.  Ab initio study of the binding of Trichostatin A (TSA) in the active site of histone deacetylase like protein (HDLP). , 2003, Organic & biomolecular chemistry.

[19]  K. Venkatasubbarao,et al.  Trichostatin A Induces Transforming Growth Factor β Type II Receptor Promoter Activity and Acetylation of Sp1 by Recruitment of PCAF/p300 to a Sp1·NF-Y Complex* , 2005, Journal of Biological Chemistry.

[20]  J. Roth,et al.  p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells , 1997, Oncogene.

[21]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[22]  M Karplus,et al.  Zinc binding in proteins and solution: A simple but accurate nonbonded representation , 1995, Proteins.

[23]  G. Thorgeirsson,et al.  Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. , 2000, The American journal of cardiology.

[24]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[25]  H. W. Lee,et al.  Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. , 2000, Cancer research.

[26]  L. Ngo,et al.  Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Jan H. Jensen,et al.  Very fast empirical prediction and rationalization of protein pKa values , 2005, Proteins.

[28]  Simak Ali,et al.  ICI182,780 Induces p21Waf1 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor α from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line* , 2005, Journal of Biological Chemistry.

[29]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[30]  Jaye L Viner,et al.  Statins and cancer--beyond the "one drug, one disease" model. , 2005, The New England journal of medicine.

[31]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[32]  Yen-Jen Oyang,et al.  MEDock: a web server for efficient prediction of ligand binding sites based on a novel optimization algorithm , 2005, Nucleic Acids Res..

[33]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[34]  Wei‐Chien Huang,et al.  Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel alpha-methylene-gamma-butyrolactone derivatives. , 2004, Carcinogenesis.

[35]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[36]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[37]  C. Langford,et al.  Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. , 2007, Genome research.

[38]  J. Thornton,et al.  Stereochemical quality of protein structure coordinates , 1992, Proteins.

[39]  R. Coffey,et al.  Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAF1/CIP1 via C/EBPβ , 1997, Nature Medicine.

[40]  J. Hung,et al.  Sp1 Deacetylation Induced by Phorbol Ester Recruits p300 To Activate 12(S)-Lipoxygenase Gene Transcription , 2006, Molecular and Cellular Biology.

[41]  M. Minden,et al.  HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis , 2002, Leukemia.

[42]  Stephen B. Gruber,et al.  Statins and cancer prevention , 2005, Nature Reviews Cancer.

[43]  F. Zindy,et al.  Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter , 2004, Oncogene.

[44]  K. Itoh,et al.  Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. , 1999, Cancer research.

[45]  C. Shun,et al.  A Novel Anticancer Effect of Thalidomide: Inhibition of Intercellular Adhesion Molecule-1–Mediated Cell Invasion and Metastasis through Suppression of Nuclear Factor-κB , 2006, Clinical Cancer Research.

[46]  O. Wiest,et al.  Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. , 2005, Journal of medicinal chemistry.

[47]  K. Kinzler,et al.  p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. , 1995, Genes & development.